Literature DB >> 22269535

The prevalence and nature of stopped on-the-road driving tests and the relationship with objective performance impairment.

Joris C Verster1, Thomas Roth.   

Abstract

INTRODUCTION AND
OBJECTIVES: The on-the-road driving test in normal traffic is applied to examine the impact of drugs on driving performance. Although participants are accompanied by a licensed driving instructor, under Dutch law, the driver is primarily responsible for safe driving and is not permitted to continue driving when it is judged that the drug compromises safety. This review examined the prevalence and nature of stopped driving tests, and the relationship with Standard Deviation of Lateral Position (SDLP), i.e. the "weaving of the car".
MATERIALS AND METHODS: A literature search was conducted to gather all publications on clinical trials that applied the on-the-road driving test, examining the effects of Central Nervous System (CNS)-drugs such as anxiolytics, antidepressants, antihistamines, analgesics, and hypnotics.
RESULTS: 47 papers reported on 50 Dutch clinical trials in which 1059 subjects participated (903 healthy volunteers and 156 patients). A total of 7232 driving tests were performed; 5050 after drug treatment and 2042 after placebo. 3.1% of all driving tests were terminated before completion: 4.1% after drug treatment, and 0.7% after placebo. The decision to stop a driving test was 3-4 times more often made by the driving instructor than the subject. The most common reasons for stopping were the driver feeling tired or sleepy, or the driving instructor noticing signs of drowsiness and performance impairment. Although SDLP values of stopped driving tests are sometimes high, there is no clear relationship between SDLP (changes from placebo) and the decision to stop a driving test. Based on 8 studies that reported exact data, 39.6% of stopped drivers had a lower and 60.4% had a higher SDLP than 35 cm, i.e. the cut-off point of safe driving. This confirms that perception of the driver as well as judgment by the instructor of driving to be 'unsafe' differs between individuals.
CONCLUSION: Driving tests are sometimes stopped after drug treatment or placebo. The decision to stop driving is not a good correlate of objective performance.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22269535     DOI: 10.1016/j.aap.2011.09.003

Source DB:  PubMed          Journal:  Accid Anal Prev        ISSN: 0001-4575


  6 in total

1.  On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.

Authors:  Annemiek Vermeeren; Hong Sun; Eric F P M Vuurman; Stefan Jongen; Cees J Van Leeuwen; Anita C M Van Oers; John Palcza; Xiadong Li; Tine Laethem; Ingeborg Heirman; An Bautmans; Matthew D Troyer; Rebecca Wrishko; Jacqueline McCrea
Journal:  Sleep       Date:  2015-11-01       Impact factor: 5.849

2.  Residual effects of low-dose sublingual zolpidem on highway driving performance the morning after middle-of-the-night use.

Authors:  Annemiek Vermeeren; Eric F P M Vuurman; Tim R M Leufkens; Cees J Van Leeuwen; Anita C M Van Oers; Eugene Laska; Salvador Rico; Frank Steinberg; Thomas Roth
Journal:  Sleep       Date:  2014-03-01       Impact factor: 5.849

3.  Sleep disorders as a cause of motor vehicle collisions.

Authors:  Marco Túlio de Mello; Fernanda Veruska Narciso; Sergio Tufik; Teresa Paiva; David Warren Spence; Ahmed S Bahammam; Joris C Verster; Seithikurippu R Pandi-Perumal
Journal:  Int J Prev Med       Date:  2013-03

4.  The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.

Authors:  Aurora J A E van de Loo; Adriana C Bervoets; Loes Mooren; Noor H Bouwmeester; Johan Garssen; Rob Zuiker; Guido van Amerongen; Joop van Gerven; Jaskaran Singh; Peter Van der Ark; Maggie Fedgchin; Randall Morrison; Ewa Wajs; Joris C Verster
Journal:  Psychopharmacology (Berl)       Date:  2017-07-28       Impact factor: 4.530

5.  On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.

Authors:  Annemiek Vermeeren; Eva Vets; Eric F P M Vuurman; Anita C M Van Oers; Stefan Jongen; Tine Laethem; Ingeborg Heirman; An Bautmans; John Palcza; Xiadong Li; Matthew D Troyer; Rebecca Wrishko; Jacqueline McCrea; Hong Sun
Journal:  Psychopharmacology (Berl)       Date:  2016-07-16       Impact factor: 4.530

6.  On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers.

Authors:  Annemiek Vermeeren; Stefan Jongen; Patricia Murphy; Margaret Moline; Gleb Filippov; Kate Pinner; Carlos Perdomo; Ishani Landry; Oneeb Majid; Anita C M Van Oers; Cees J Van Leeuwen; Johannes G Ramaekers; Eric F P M Vuurman
Journal:  Sleep       Date:  2019-04-01       Impact factor: 5.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.